| Elssy N. Oms Md Pa | |
|
400 S Australian Ave Ste 422 West Palm Beach FL 33401-5004 | |
| (561) 295-7070 | |
| Not Available |
| Full Name | Elssy N. Oms Md Pa |
|---|---|
| Speciality | Psychiatry & Neurology |
| Location | 400 S Australian Ave Ste 422, West Palm Beach, Florida |
| Authorized Official Name and Position | Elssy Oms (PRESIDENT) |
| Authorized Official Contact | 7868539159 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Elssy N. Oms Md Pa 400 S Australian Ave Ste 422 West Palm Beach FL 33401-5004 Ph: (786) 853-9159 | Elssy N. Oms Md Pa 400 S Australian Ave Ste 422 West Palm Beach FL 33401-5004 Ph: (561) 295-7070 |
| NPI Number | 1336856319 |
|---|---|
| Provider Enumeration Date | 10/31/2022 |
| Last Update Date | 11/09/2022 |
| Certification Date | 11/09/2022 |
| Medicare PECOS PAC ID | 0042689416 |
|---|---|
| Medicare Enrollment ID | O20221206002548 |
News Archive
Following a brain-injuring bump or blow to the head, brain cells and blood vessels typically swell. This can lead to a potentially life-threatening increase in pressure inside the skull, and managing swelling is critical for patients with traumatic brain injuries (TBIs).
Global Post examines how "many HIV patients around the world continue to turn to more affordable but far less reliable treatments" instead of proven - but more expensive - therapies, such as antiretroviral (ARV) drugs.
Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.
A report released Monday by the WHO and UNICEF documents mixed progress in improving drinking water and sanitation conditions worldwide, VOA News reports (Schlein, 3/15). "The report - presenting the latest data on improved sources of sanitation and drinking water in 209 countries or territories - is aimed at assisting policy-makers, donors, government and non-governmental agencies decide what needs to be done," U.N. News Centre writes (3/15).
GenomOncology today announced a collaboration with Roswell Park Cancer Institute (RPCI) to develop an informatics solution that enables the association of Next Generation Sequencing results with knowledge resources to define actionable mutations.
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336856319 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | (* (Not Available)) | Primary |
| 2084P0804X | Psychiatry & Neurology - Child & Adolescent Psychiatry | (* (Not Available)) | Secondary |
| Provider Name | Elssy N Oms |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1528099561 PECOS PAC ID: 8527195205 Enrollment ID: I20100429000245 |
News Archive
Following a brain-injuring bump or blow to the head, brain cells and blood vessels typically swell. This can lead to a potentially life-threatening increase in pressure inside the skull, and managing swelling is critical for patients with traumatic brain injuries (TBIs).
Global Post examines how "many HIV patients around the world continue to turn to more affordable but far less reliable treatments" instead of proven - but more expensive - therapies, such as antiretroviral (ARV) drugs.
Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.
A report released Monday by the WHO and UNICEF documents mixed progress in improving drinking water and sanitation conditions worldwide, VOA News reports (Schlein, 3/15). "The report - presenting the latest data on improved sources of sanitation and drinking water in 209 countries or territories - is aimed at assisting policy-makers, donors, government and non-governmental agencies decide what needs to be done," U.N. News Centre writes (3/15).
GenomOncology today announced a collaboration with Roswell Park Cancer Institute (RPCI) to develop an informatics solution that enables the association of Next Generation Sequencing results with knowledge resources to define actionable mutations.
› Verified 3 days ago
News Archive
Following a brain-injuring bump or blow to the head, brain cells and blood vessels typically swell. This can lead to a potentially life-threatening increase in pressure inside the skull, and managing swelling is critical for patients with traumatic brain injuries (TBIs).
Global Post examines how "many HIV patients around the world continue to turn to more affordable but far less reliable treatments" instead of proven - but more expensive - therapies, such as antiretroviral (ARV) drugs.
Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.
A report released Monday by the WHO and UNICEF documents mixed progress in improving drinking water and sanitation conditions worldwide, VOA News reports (Schlein, 3/15). "The report - presenting the latest data on improved sources of sanitation and drinking water in 209 countries or territories - is aimed at assisting policy-makers, donors, government and non-governmental agencies decide what needs to be done," U.N. News Centre writes (3/15).
GenomOncology today announced a collaboration with Roswell Park Cancer Institute (RPCI) to develop an informatics solution that enables the association of Next Generation Sequencing results with knowledge resources to define actionable mutations.
› Verified 3 days ago
Rehab South Florida Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 4460 Medical Center Way, West Palm Beach, FL 33407 Phone: 863-532-3151 | |
Salonia Psychotherapy Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1825 Forest Hill Blvd., #105, West Palm Beach, FL 33406 Phone: 954-650-6907 | |
Sunshine Of Tomorrow Behavioral Care Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 7711 N Military Trl Ste 204, West Palm Beach, FL 33410 Phone: 561-914-4104 | |
Diosark, Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1546 42nd St, West Palm Beach, FL 33407 Phone: 561-840-1647 Fax: 561-840-6415 | |
Crossroads Counseling Center Of The Palm Beaches Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1825 Forest Hill Blvd, Suite 105, West Palm Beach, FL 33406 Phone: 561-722-7084 Fax: 561-697-9925 | |
Wellbeing Therapy Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 7750 Okeechobee Blvd # 4-76, West Palm Beach, FL 33411 Phone: 772-678-0341 | |
Be Free Stay Free Family & Individual Therapy Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 3626 Whitehall Dr Apt 206, West Palm Beach, FL 33401 Phone: 561-377-2373 |